scholarly journals ACTH secreting pituitary carcinoma: Rare, durable response to concurrent chemotherapy and re-irradiation with a review of the literature. Recurrent pituitary carcinoma re-irradiation

2021 ◽  
pp. 100813
Author(s):  
Megan Orr ◽  
James Findling ◽  
Nathan Zwagerman ◽  
Jennifer Connelly ◽  
Katherine Albano ◽  
...  
Keyword(s):  
Concurrent Chemotherapy ◽  
Pituitary Carcinoma ◽  
Review Of The Literature ◽  
Durable Response ◽  
Acth Secreting

scholarly journals Marked Response of a Hypermutated ACTH-Secreting Pituitary Carcinoma to Ipilimumab and Nivolumab

2018 ◽  
Vol 103 (10) ◽  
pp. 3925-3930 ◽  
Author(s):  
Andrew L Lin ◽  
Philip Jonsson ◽  
Viviane Tabar ◽  
T Jonathan Yang ◽  
John Cuaron ◽  
...  
Keyword(s):  
Pituitary Adenoma ◽  
Liver Metastasis ◽  
Effective Treatment ◽  
Somatic Hypermutation ◽  
Treatment Options ◽  
Pituitary Tumors ◽  
Pituitary Carcinoma ◽  
Tumor Resistance ◽  
Clinical Sequencing ◽  
Acth Secreting

Abstract Context Pituitary carcinoma is a rare and aggressive malignancy with a poor prognosis and few effective treatment options. Case A 35-year-old woman presented with an aggressive ACTH-secreting pituitary adenoma that initially responded to concurrent temozolomide and capecitabine prior to metastasizing to the liver. Following treatment with ipilimumab and nivolumab, the tumor volume of the dominant liver metastasis reduced by 92%, and the recurrent intracranial disease regressed by 59%. Simultaneously, her plasma ACTH level decreased from 45,550 pg/mL to 66 pg/mL. Molecular Evaluation Both prospective clinical sequencing with Memorial Sloan Kettering–Integrated Mutation Profiling of Actionable Cancer Targets and retrospective whole-exome sequencing were performed to characterize the molecular alterations in the chemotherapy-naive pituitary adenoma and the temozolomide-resistant liver metastasis. The liver metastasis harbored a somatic mutational burden consistent with alkylator-induced hypermutation that was absent from the treatment-naive tumor. Resistance to temozolomide treatment, acquisition of new oncogenic drivers, and subsequent sensitivity to immunotherapy may be attributed to hypermutation. Conclusion Combination treatment with ipilimumab and nivolumab may be an effective treatment in pituitary carcinoma. Clinical sequencing of pituitary tumors that have relapsed following treatment with conventional chemotherapy may identify the development of therapy-induced somatic hypermutation, which may be associated with treatment response to immunotherapy.

scholarly journals Durable Control of Mycosis Fungoides after Sepsis: “Coley’s Toxin?” Case Report and Review of the Literature

2019 ◽  
Vol 2019 ◽  
pp. 1-4
Author(s):  
Benjamin Heyman ◽  
Chris R. Kelsey ◽  
Anne Beaven
Keyword(s):  
Staphylococcus Aureus ◽  
Immune Response ◽  
Mycosis Fungoides ◽  
Cell Lymphoma ◽  
Single Agent ◽  
Severe Infection ◽  
Advanced Stage ◽  
Cutaneous T Cell Lymphoma ◽  
Review Of The Literature ◽  
Durable Response

Mycosis fungoides, along with Sezary syndrome, is the most common subtype of cutaneous T-cell lymphoma. In this report, we present a patient with advanced-stage mycosis fungoides, who after successful treatment of methicillin-resistantStaphylococcus aureusbacteremia had prolonged disease control off systemic therapy. While this may have been due to single-agent gemcitabine, which can result in long remission, we hypothesize that our patient’s durable response was in part due to the immune response elicited after treatment of her severe infection.

Pituitary carcinoma: Report of an exceptional case and review of the literature

2002 ◽  
Vol 25 (1) ◽  
pp. 65-72 ◽  
Author(s):  
C. Pichard ◽  
S. Gerber ◽  
M. Laloi ◽  
M. Kujas ◽  
S. Clemenceau ◽  
...  
Keyword(s):  
Exceptional Case ◽  
Pituitary Carcinoma ◽  
Review Of The Literature

scholarly journals Durable response in a thymic neuroendocrine tumor: A case report and review of the literature

2017 ◽  
Vol 7 (2) ◽  
pp. 23
Author(s):  
Yusef A. Syed ◽  
Daniel H. Miller ◽  
Liuyan Jiang ◽  
Arya Bagherpour ◽  
Stephen J. Ko
Keyword(s):  
Neuroendocrine Tumors ◽  
Randomized Clinical Trials ◽  
Treatment Guidelines ◽  
Treatment Approach ◽  
Case Reports ◽  
Adjuvant Radiation ◽  
Review Of The Literature ◽  
Durable Response ◽  
Complete Surgical Resection ◽  
And Behavior

Thymic neuroendocrine tumors are rare, representing less than 5% of all thymic cancers, and are biologically distinct in histology and behavior. Conclusive treatment guidelines are limited due to a lack of randomized clinical trials. Current literature, consisting mainly of case reports and series, suggests that complete surgical resection combined with adjuvant radiation therapy offers the greatest survival benefit for patients with thymic neuroendocrine tumors (NET). Adjuvant chemotherapy may also delay the onset of distant metastasis. Prognosis is generally poor, particularly in high-grade tumors, as these patients are prone to early metastasis. Here we present the case of a 62-year-old woman who achieved a durable response after undergoing an aggressive multimodal treatment approach for a primary thymic NET that initially presented as chronic cough and mild dyspnea on exertion.

scholarly journals Immune checkpoint inhibitor therapy for ACTH-secreting pituitary carcinoma: a new emerging treatment?

2021 ◽  
Vol 184 (1) ◽  
pp. K1-K5 ◽  
Author(s):  
Bastiaan Sol ◽  
Jeroen M K de Filette ◽  
Gil Awada ◽  
Steven Raeymaeckers ◽  
Sandrine Aspeslagh ◽  
...  
Keyword(s):  
Case Report ◽  
Immune Checkpoint ◽  
Checkpoint Inhibitors ◽  
Case Reports ◽  
Pituitary Carcinoma ◽  
Disease Stabilization ◽  
Checkpoint Inhibitor Therapy ◽  
Promising Treatment ◽  
Acth Secreting

Background Pituitary carcinomas are rare but aggressive and require maximally coordinated multimodal therapies. For refractory tumors, unresponsive to temozolomide (TMZ), therapeutic options are limited. Immune checkpoint inhibitors (ICI) may be considered for treatment as illustrated in the present case report. Case We report a patient with ACTH-secreting pituitary carcinoma, progressive after multiple lines of therapy including chemotherapy with TMZ, who demonstrated disease stabilization by a combination of ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1) ICI therapy. Discussion Management of pituitary carcinoma beyond TMZ remains ill-defined and relies on case reports. TMZ creates, due to hypermutation, more immunogenic tumors and subsequently potential candidates for ICI therapy. This case report adds support to the possible role of ICI in the treatment of pituitary carcinoma. Conclusion ICI therapy could be a promising treatment option for pituitary carcinoma, considering the mechanisms of TMZ-induced hypermutation with increased immunogenicity, pituitary expression of CTLA-4 and PD-L1, and the frequent occurrence of hypophysitis as a side effect of ICI therapy.

scholarly journals Long-Term Survival with ACTH-Secreting Carcinoma of the Pituitary: A Case Report and Review of the Literature

2002 ◽  
Vol 87 (7) ◽  
pp. 3084-3089 ◽  
Author(s):  
Rita E. Landman ◽  
Melvin Horwith ◽  
Ralph E. Peterson ◽  
Alexander G. Khandji ◽  
Sharon L. Wardlaw
Keyword(s):  
Case Report ◽  
Review Of The Literature ◽  
Term Survival ◽  
Long Term Survival ◽  
Acth Secreting

Double pituitary adenomas are most commonly associated with GH- and ACTH-secreting tumors: systematic review of the literature

Pituitary ◽  
2017 ◽  
Vol 20 (6) ◽  
pp. 702-708 ◽  
Author(s):  
Elizabeth Ogando-Rivas ◽  
Andrew F. Alalade ◽  
Jerome Boatey ◽  
Theodore H. Schwartz
Keyword(s):  
Systematic Review ◽  
Pituitary Adenomas ◽  
Review Of The Literature ◽  
Double Pituitary Adenomas ◽  
Acth Secreting

INVASIV GEWACHSENES BASOPHILES ADENOM DES HYPOPHYSENVORDERLAPPENS BEI CUSHING-SYNDROM

1963 ◽  
Vol 43 (3) ◽  
pp. 330-344 ◽  
Author(s):  
J. Kracht ◽  
J. Tamm
Keyword(s):  
Case Report ◽  
Surgical Treatment ◽  
Cushing’S Syndrome ◽  
Anterior Pituitary ◽  
Cushing's Syndrome ◽  
List Type ◽  
Review Of The Literature ◽  
Pituitary Tumours ◽  
Histological Criteria ◽  
Acth Secreting

ABSTRACT A case report is presented of a female patient with an invasive basophil adenoma of the anterior pituitary gland and with Cushing's syndrome. Following a review of the literature of Cushing's syndrome with expanding and invasive pituitary tumours with and without metastases we have divided these tumours into three groups: Pituitary tumours, which arise with no surgical treatment of the adrenals. Tumours of category 1, the growth of which is accelerated following adrenalectomy. Tumours whose growth is accelerated following adrenalectomy, but which are recognized clinically only after surgical treatment of the adrenals. Most of these tumours are now considered to be »hyperplasiogenic« growths, which continue to remain under the influence of hypothalamic factors. Primary autonomous, ACTH-secreting tumours are on the contrary seldom seen. Histological criteria are insufficient to differentiate between autonomous and regulated pituitary ACTH-producing tumours. It is assumed that this differentiation may be only possible by means of function-tests.

Sign in / Sign up

Export Citation Format

Share Document